The original disclosure in Japanese was released on August 4, 2020 at 15:30 (GMT+9)

Consolidated Financial Statements for the First Quarter Ended June 30, 2020
FY2021(April 1, 2020 - March 31, 2021) [UNAUDITED]

Company name: Takara Holdings Inc.
Stock exchange listings: Tokyo Stock Exchange (1st section)
Code number: 2531
URL: https://www.takara.co.jp/
Company representative: Mutsumi Kimura, President
Contact: Masakazu Usami, General Manager of Financial & Investor Relations Dept.
TEL : (075)241-5124

Quarterly statement filing date (as planned): August 12, 2020

Notes:
1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.

1. Results for the three months ended June 30, 2020 (April 1, 2020 - June 30, 2020)

(1) Consolidated Operating results

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Three months ended June 30, 2020		Three months ended June 30, 2019	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	65,378	(2.9)	67,317	0.5
Operating income (loss)	1,932	(45.5)	3,548	(11.3)
Ordinary income (loss)	2,187	(44.1)	3,912	(9.2)
Net income (loss) attributable to owners of the parent	1,156	(41.3)	1,969	(15.7)
Net income (loss) per share (Yen)	5.85		9.87	
Fully diluted net income per share (Yen)	-		-	
Note: Comprehensive income (loss)	3	(99.8)	2,220	-

(2) Consolidated Financial position

	As of June 30, 2020	As of March 31, 2020
	(Millions of yen)	(Millions of yen)
Total assets	288,981	283,882
Net assets	176,980	181,329
Equity ratio (%)	49.9	52.1
(Reference) Equity	144,122	147,762

2. Dividends

	Dividend per share (Yen)		
	Year ended March 31, 2020	Year ending March 31, 2021	Year ending March 31, 2021(Forecast)
First quarter end	-	-	
Second quarter end	-		-
Third quarter end	-		-
Year end	20.00		20.00
Annual	20.00		20.00

Note: Correction of dividend forecast from the most recent dividend forecast : No

3. Forecast for the year ending March 31, 2021 (April 1, 2020 - March 31, 2021)

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Six months ending September 30, 2020		Year ending March 31, 2021	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	122,504	(10.9)	275,800	(1.9)
Operating income (loss)	2,180	(71.4)	12,000	(24.2)
Ordinary income (loss)	2,265	(71.2)	12,200	(25.0)
Net income (loss) attributable to owners of the parent	760	(82.6)	5,952	(33.7)
Net income per share (Yen)	3.84		30.11	

Note: Correction of financial forecast from the most recent financial forecast : Yes

4. Others

(1) Material changes in subsidiaries during this period
(Changes in specified subsidiaries that caused a change in the scope of consolidation) : No

(2) Accounting procedures specific to quarterly consolidated financial statements : No

(3) Changes in accounting policies, accounting estimates and retrospective restatement

1) Changes based on revisions of accounting standard : No

2) Changes other than ones based on revisions of accounting standard : No

3) Changes in accounting estimates : No

4) Restatement : No

(4) Number of outstanding shares (common stock)

1) Number of outstanding shares at the end of each period (Treasury stocks are included):

As of June 30, 2020 : 199,699,743 shares

As of March 31, 2020 : 199,699,743 shares

2) Number of treasury stocks at the end of each period:

As of June 30, 2020 : 1,995,058 shares

As of March 31, 2020 : 1,995,163 shares

3) Average number of outstanding shares in each period

Three months ended June 30, 2020 : 197,704,620 shares

Three months ended June 30, 2019 : 199,630,037 shares

Contents of the attached document

1. Qualitative Information for the Three Months Ended June 30, 2020 …… 2

(1) Consolidated Financial Results …… 2

(2) Consolidated Financial Position …… 3

(3) Qualitative Information Regarding Consolidated Forecasts …… 4

2. Consolidated Quarterly Financial Statements and Primary Notes …… 5

(1) Consolidated Balance Sheets …… 5

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income …… 7

(Consolidated Statements of Income) …… 7
(For the Three Months Ended June 30, 2020 and 2019)

(Consolidated Statements of Comprehensive Income) …… 8
(For the Three Months Ended June 30, 2020 and 2019)

(3) Notes on Consolidated Financial Statements …… 9

(Notes on Premise of Going Concern) …… 9

(Notes on Material Changes in Shareholders' Equity) …… 9

(Segment Information) …… 9

(Significant Subsequent Events) …… 10

○ Supplement for the Consolidated Quarterly Financial Statements

1. Qualitative Information for the Three Months Ended June 30, 2020

(1) Consolidated Financial Results

In the three months ended June 30, 2020, the Japanese economy encountered restrictions on various economic activities due to the effects of COVID-19. Predicting what might lie ahead poses substantial difficulties amid a scenario where spread of the infection could emerge again, despite previously perceived to have been winding down. Overseas, the outlook remains uncertain as is the case with Japan, largely given mounting tensions surrounding trade issues particularly involving the U.S. and China, compounded by worldwide prevalence of the COVID-19 pandemic.

Under these economic circumstances, the Group has been working hard toward achieving sustainable growth both in Japan and overseas, and enhancing the Group's corporate value. To such ends, the Group has been flexibly addressing environmental changes including ramifications of COVID-19, appropriately allocating and investing management resources in areas that should be strengthened, and promoting efforts to rebuild business structures and global corporate functions such that consistently generate various forms of value that enhance profitability, underpinned by the Takara Group Medium-Term Management Plan for FY2021-2023 which serves as the first step in the Group's action plans cited in its long-term management vision, TaKaRa Group Challenge for the 100th.

As a result, in three months ended June 30, 2020, net sales were down 2.9% year on year to ¥65,378 million. Gross profit fell 4.2% year on year to ¥25,358 million. Operating income decreased by 45.5% year on year to ¥1,932 million, while ordinary income fell 44.1% year on year to ¥2,187 million. Net income attributable to owners of the parent decreased by 41.3% year on year to ¥1,156 million.

Results by business segment were as follows.

[Takara Shuzo]

In the three months ended June 30, 2020, net sales varied widely from category to category as a result of dining establishments and other such entities voluntarily restricting business operations and also due to so-called stay-at-home demand. For alcoholic beverages, sales of sake decreased but sales of light-alcohol refreshers overall increased given that sales of light-alcohol refreshers remained robust. In seasonings, sales decreased slightly despite an increase in sales of other seasonings, due to lower sales of mirin. Sales of raw alcohol and other products increased due to strong sales of industrial alcohol.

As a result, net sales for the Takara Shuzo Group rose 4.4% year on year to ¥37,601 million. Cost of sales increased 5.2% year on year to ¥23,015 million. Consequently, gross profit rose 3.2% year on year to ¥14,586 million. SG&A expenses were down by 0.8% year on year to ¥13,854 million due to decreases in advertisement expenses and other expenses, and operating income was up 323.6% year on year to ¥731 million.

[Takara Shuzo International Group]

In the three months ended June 30, 2020, net sales remained on par with those of the previous fiscal year overall amid a situation whereby the Overseas Alcoholic Beverages Business generated robust sales of whiskey in the U.K. and the U.S., but was substantially affected by COVID-19 in China. Meanwhile, the Japanese Food Wholesale Business in overseas markets encountered a decrease in sales largely due to closures since March of restaurants who serve as the Company's primary customers in Europe and the U.S. Moreover, net sales converted to Japanese yen decreased due to effects of a stronger yen than in the same period of the previous fiscal year.

As a result, net sales for the Takara Shuzo International Group decreased 6.1% year on year to ¥18,616 million. Cost of sales decreased 7.2% year on year to ¥13,237 million. Consequently, gross profit fell 3.3% year on year to ¥5,379 million. SG&A expenses were up 7.5% year on year to ¥5,245 million due to increases in administrative expenses and other expenses, and operating income was down 80.4% year on year to ¥133 million.

[Takara Bio Group]

In the three months ended June 30, 2020, net sales were down 19.8% year on year to ¥6,938 million due to lower sales in gene therapy. Cost of sales fell 18.3% year on year to ¥2,234 million largely due to the decrease in net sales, and gross profit decreased 20.5% year on year to ¥4,703 million. SG&A expenses were up 9.4% year on year to ¥4,009 million due to increases in research and development expenses and other expenses, and operating income was down 69.2% year on year to ¥693 million.

[Other]

In the three months ended June 30, 2020, net sales of the Other segment declined 10.7% year on year to ¥6,858 million largely due to effects of the spread of COVID-19. Cost of sales declined 9.3% year on year to ¥6,033 million. Consequently, gross profit decreased 19.8% year on year to ¥825 million. SG&A expenses fell 7.7% year on year to ¥473 million, and operating income was down 31.9% year on year to ¥352 million.

Breakdown of sales results by product category

Segment	Equivalent Period of Previous Fiscal Year (From April 1, 2019, to June 30, 2019)	Period under Review (from April 1, 2020, to June 30, 2020)	YoY Comparison
Product category	Amount (Millions of yen)	Amount (Millions of yen)	(%)
Takara Shuzo			
Shochu	12,297	12,445	101.2
Sake	4,111	3,507	85.3
Light-alcohol refreshers	10,047	11,886	118.3
Other alcoholic beverages	1,592	1,352	84.9
Alcoholic beverages total	28,048	29,191	104.1
Hon Mirin	3,191	3,127	98.0
Other seasonings	2,423	2,461	101.6
Seasonings total	5,614	5,589	99.6
Raw alcohol, etc.	2,345	2,821	120.3
Total	36,009	37,601	104.4
Takara Shuzo International Group			
Overseas Alcoholic Beverages Business	2,493	2,506	100.5
Japanese Food Wholesales Business in overseas markets	17,774	16,460	92.6
Other	24	28	113.0
Elimination of intra-Group transaction on consolidation	(473)	(379)	—
Total	19,819	18,616	93.9
Takara Bio Group	8,650	6,938	80.2
Reported segment total	64,479	63,156	97.9
Other	7,682	6,858	89.3
Segment total	72,161	70,014	97.0
Sales not allocated to business segments and intersegment transactions	(4,844)	(4,635)	—
Total	67,317	65,378	97.1

Note: Amounts include alcohol tax but do not include consumption tax.

(2) Consolidated Financial Position

As of June 30, 2020, current assets were ¥174,397 million, an increase of ¥5,577 million compared with that at the end of the previous fiscal year. This was primarily due to an increase in cash and deposits of ¥4,399 million. Noncurrent assets were ¥114,584 million, a decrease of ¥477 million compared with that at the end of the previous fiscal year.

As a result, total assets were ¥288,981 million, an increase of ¥5,099 million compared with that at the end of the previous fiscal year.

As of June 30, 2020, current liabilities were ¥55,055 million, an decrease of ¥411 million compared with that at the end of the previous fiscal year. Noncurrent liabilities were ¥56,945 million, a decrease of ¥9,859 million compared with that at the end of the previous fiscal year. This was due to an increase in long-term loans payable of ¥9,957 million.

As a result, total liabilities were ¥112,001 million, an increase of ¥9,448 million compared with that at the end of the previous fiscal year.

As of June 30, 2020, total net assets were ¥176,980 million, an decrease of ¥4,348 million compared with that at the end of the previous fiscal year. This was primarily due to decreases in retained earnings of ¥2,797 million and foreign currency translation adjustment of ¥1,613 million.

As a result, the equity ratio totaled 49.9%, compared with 52.1% at the end of the previous fiscal year.

(3) Qualitative Information Regarding Consolidated Forecasts

The Company has revised the consolidated results forecasts for the six months ending September 30, 2020, and the fiscal year ending March 31, 2021, in view of the consolidated business results in the three months ended June 30, 2020, and recent circumstances.

In the three months ended June 30, 2020, Takara Shuzo and Takara Shuzo International Group largely exceeded the internal targets. Nevertheless, the Company has decided to leave the initial forecast unchanged given a situation where effects of COVID-19 had been expected to persist until sometime around July 2020, but now seem likely to continue for a longer period of time.

Moreover, Takara Bio Group has revised its consolidated results forecasts for the six months ending September 30, 2020, and the fiscal year ending March 31, 2021, upon having accounted for factors that seem likely at this point of time, including potential contributions to financial results particularly from polymerase chain reaction (PCR)-related products for COVID-19 testing and contract manufacturing services involving DNA vaccines, and also upon having accounted for effects of having terminated Takara Bio's agreement for exclusive development, manufacturing and sales of oncolytic viral immunotherapy agent C-REV (canerpaturev) in China, announced on August 4, 2020.

Accordingly, the Company has revised the Group's consolidated results forecasts for the six months ending September 30, 2020, and the fiscal year ending March 31, 2021, as follows. Please refer pages 8/9 to 9/9 in "Supplement for the Consolidated Financial Statements" for further details.

(Consolidated results forecasts for the six months ending September 30, 2020)

	Net sales	Operating income	Ordinary income	Net income attributable to owners of the parent	Net income per share
Previous forecast (A) (Published May 14, 2020)	(Millions of yen) 120,000	(Millions of yen) 300	(Millions of yen) 400	(Millions of yen) 0	(Yen) 0.00
Revised forecast (B)	122,504	2,180	2,265	760	3.84
Difference (B－A)	2,504	1,880	1,865	760	－
Difference (%)	2.1	626.7	466.3	－	－
Reference: Business results for previous fiscal year (Ended September 30, 2019)	137,502	7,623	7,871	4,374	21.91

(Full-Year Consolidated Results Forecasts for the fiscal year ending March 31, 2021)

	Net sales	Operating income	Ordinary income	Net income attributable to owners of the parent	Net income per share
Previous forecast (A) (Published May 14, 2020)	(Millions of yen) 270,000	(Millions of yen) 10,000	(Millions of yen) 10,200	(Millions of yen) 5,100	(Yen) 25.80
Revised forecast (B)	275,800	12,000	12,200	5,952	30.11
Difference (B－A)	5,800	2,000	2,000	852	－
Difference (%)	2.1	20.0	19.6	16.7	－
Reference: Business results for previous fiscal year (Ended March 31, 2020)	281,191	15,836	16,269	8,980	45.11

2. Consolidated Financial Statements and Primary Notes

(1) Consolidated Balance Sheets

(Millions of Yen)

	As of Mar. 31, 2020	As of June 30, 2020
Assets		
Current assets		
Cash and deposits	47,265	51,664
Notes and accounts receivable-trade	61,017	59,563
Securities	7,352	7,324
Merchandise and finished goods	42,295	44,029
Work in process	1,801	1,937
Raw materials and supplies	4,879	5,473
Other	4,515	4,812
Allowance for doubtful accounts	(307)	(408)
Total current assets	168,820	174,397
Noncurrent assets		
Property, plant and equipment	69,835	69,210
Intangible assets		
Goodwill	11,750	11,294
Other	6,950	6,569
Total intangible assets	18,700	17,864
Investments and other assets		
Investment securities	21,720	22,768
Other	4,873	4,809
Allowance for doubtful accounts	(69)	(69)
Total investments and other assets	26,525	27,509
Total noncurrent assets	115,061	114,584
Total assets	283,882	288,981

(Millions of Yen)

	As of Mar. 31, 2020	As of June 30, 2020
Liabilities		
Current liabilities		
Notes and accounts payable-trade	16,440	16,469
Short-term loans payable	4,787	4,916
Commercial papers	—	5,000
Current portion of bonds	5,000	—
Accrued alcohol tax	7,690	7,521
Accrued expenses	5,511	4,272
Income taxes payable	1,886	829
Provision for bonuses	2,513	3,585
Other provision	2,711	2,837
Other	8,926	9,623
Total current liabilities	55,466	55,055
Noncurrent liabilities		
Bonds payable	20,000	20,000
Long-term loans payable	5,448	15,405
Lease obligations	3,538	3,241
Net defined benefit liability	9,065	9,115
Long-term deposits received	5,363	5,373
Other	3,670	3,808
Total noncurrent liabilities	47,086	56,945
Total liabilities	102,553	112,001
Net assets		
Shareholders' equity		
Capital stock	13,226	13,226
Capital surplus	2,454	2,454
Retained earnings	128,564	125,766
Treasury stock	(1,682)	(1,681)
Total shareholders' equity	142,563	139,765
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	7,125	7,851
Deferred gains or losses on hedges	84	123
Foreign currency translation adjustment	(1,102)	(2,715)
Remeasurements of defined benefit plans	(908)	(902)
Total accumulated other comprehensive income	5,199	4,356
Noncontrolling interests	33,566	32,858
Total net assets	181,329	176,980
Total liabilities and net assets	283,882	288,981

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income

(Consolidated Statements of Income)

(For the Three Months Ended June 30, 2020 and 2019)

(Millions of Yen)

	FY2020 (April 1, 2019 – June 30, 2019)	FY2021 (April 1, 2020 – June 30, 2020)
Net sales	67,317	65,378
Cost of sales	40,844	40,020
Gross profit	26,473	25,358
Selling, general and administrative expenses	22,924	23,426
Operating income	3,548	1,932
Nonoperating income		
Dividends income	314	267
Other	315	208
Total nonoperating income	630	476
Nonoperating expenses		
Interest expenses	101	99
Commission for syndicated loans	—	54
Other	165	68
Total nonoperating expenses	266	222
Ordinary income	3,912	2,187
Extraordinary income		
Gain on sales of noncurrent assets	1	0
Total extraordinary income	1	0
Extraordinary loss		
Loss on sales and retirement of non-current assets	113	19
Loss on valuation of investment securities	74	5
Other	2	—
Total extraordinary losses	190	25
Income before income taxes	3,723	2,161
Income taxes-current	1,401	1,081
Income taxes-deferred	(295)	(154)
Total income taxes	1,105	927
Net income	2,617	1,234
Net income attributable to the noncontrolling interest	647	78
Net income attributable to owners of the parent	1,969	1,156

(Consolidated Statements of Comprehensive Income)

(For the Three Months Ended June 30, 2020 and 2019)

(Millions of Yen)

	FY2020 (April 1, 2019 – June 30, 2019)	FY2021 April 1, 2020– June 30, 2020)
Net income	2,617	1,234
Other comprehensive income		
Valuation difference on available-for-sale securities	(710)	725
Deferred gains or losses on hedges	(66)	38
Foreign currency translation adjustment	389	(2,006)
Remeasurements of defined benefit plans	(10)	10
Total other comprehensive income	(397)	(1,231)
Comprehensive income	2,220	3
(Comprehensive income attributable to)		
Comprehensive income attributable to owners of the parent	1,421	313
Comprehensive income attributable to noncontrolling interest	798	(310)

(3) Notes to Consolidated Financial Statements

(Notes on Premise of Going Concern)

No items to report.

(Notes on Material Changes in Shareholders' Equity)

No items to report.

(Segment Information)

I. Equivalent Period of Previous Fiscal Year (From April 1, 2019 to June 30, 2019)

1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal				
Net sales								
External customers	35,874	19,766	8,650	64,290	3,023	67,313	3	67,317
Intersegment	134	53	0	188	4,659	4,847	(4,847)	-
Total	36,009	19,819	8,650	64,479	7,682	72,161	(4,844)	67,317
Segment income (loss)	172	678	2,251	3,102	517	3,619	(71)	3,548

Notes: 1. Other includes business segments that are not part of reported segments, such as the real estate rental business and the transportation business of domestic Group companies among others.

2. Details of adjustment amounts are as follows.

(1) Net sales to external customers are income from business contracting recorded at the Company.

(2) Segment income (loss) comprises intersegment eliminations of ¥21 million and loss of the Company not allocated to business segments of ¥(92) million.

3. Segment income (loss) has been adjusted to the operating income of consolidated quarterly statements of income.

2. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment

No items to report.

II. Period under Review (From April 1, 2020, to June 30, 2020)

1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo Group	Takara Shuzo International Group	Takara Bio Group	Subtotal				
Net sales								
External customers	37,515	18,536	6,938	62,990	2,388	65,378	0	65,378
Intersegment	86	79	-	165	4,470	4,635	(4,635)	-
Total	37,601	18,616	6,938	63,156	6,858	70,014	(4,635)	65,378
Segment income (loss)	731	133	693	1,558	352	1,910	21	1,932

Notes: 1. Other includes business segments that are not part of reported segments, such as the real estate rental business and the transportation business of domestic Group companies among others.

2. Details of adjustment amounts are as follows.
(1) Net sales to external customers are income from business contracting recorded at the Company.
(2) Segment income (loss) comprises intersegment eliminations of ¥41 million and loss of the Company not allocated to business segments of ¥(19) million.
3. Segment income (loss) has been adjusted to the operating income of consolidated quarterly statements of income.

2. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment
No items to report.

(Significant Subsequent Events)

(Significant termination of the agreement)

Takara Bio Inc., a consolidated subsidiary of the Company,has resolved to terminate the licensing agreement for oncolytic virus canerpaturev (Abbreviated to C-REV) concluded with Tasly Biopharmaceuticals Co, Ltd.(headquarters in Shanghai, People's of China; hereafter Tasly) at the board of directors' meeting held on August 4, 2020 and terminated the agreement on the same date.

1. Reason for the agreement termination
Takara Bio entered into this agreement on 11 May, 2020. After mutual discussions on future policies, it agreed to terminate the agreement on 4 August, 2020, taking into account the recent social situation (the worldwide outbreak of COVID-19) and other factors.

2. Name of the counterparty to the agreement
Tasly Biopharmaceuticals Co., Ltd.

3. Date of the agreement termination
August 4, 2020

4. Details of the agreement
Takara Bio grants Tasly the exclusive rights to develop, manufacture and commercialize C-REV in China (including Hong Kong and Macao, excluding Taiwan). The Company transfers the manufacturing technology of C-REV, and Tasly is advancing clinical development with the aim of commercializing C-REV to the market as a new anticancer agent in China.
Takara Bio receives upfront, annual and milestone payments depending on the achievement certain development from Tasly. Following launch, the Company also receives running royalty on net sales and milestone payments upon the achievement of target sales.

5. Significant impact of termination of agreement on business activities, etc..
The exclusive development, manufacturing and commercial rights of C-REV licensed to Tasley under this agreement in China will all be returned to Takara Bio upon termination of this agreement, and Takara Bio will not be able to expect the sales revenues from milestones due to development and commercial progress. On 4 August, 2020, the Company announced a revised consolidated earnings forecast for the fiscal year ending 31 March, 2021, including the impact of termination of the contract.

2021年3月期
第1四半期決算短信補足資料

Supplement for the Consolidated Financial Statements
for the First Quarter Ended June 30, 2020

1. 宝ホールディングス(連結)
Takara Holdings Inc. -Consolidated-

グループ別要約損益計算書
Consolidated Statements of Income by Business Group (Summary)

2. 宝酒造
Takara Shuzo

要約損益計算書
Statements of Income (Summary)

3. 宝酒造インターナショナルグループ
Takara Shuzo International Group

要約損益計算書
Statements of Income (Summary)

4. タカラバイオグループ
Takara Bio Group

要約損益計算書
Statements of Income (Summary)

5. 6年間の財務サマリー(グループ別)
Six-Year Financial Summary by Business Group

6. 2021年3月期第1四半期　参考資料
Reference Data for the First Quarter Ended June 30, 2020

7. 連結業績予想数値の修正
Revision of Consolidated Business Results Forecast

宝ホールディングス株式会社
TAKARA HOLDINGS INC.

財務・IR部 Financial & Investor Relations Dept.
TEL 075(241)5124
FAX 075(241)5127
E-Mail ir@takara.co.jp

将来見通しに関する注意事項

この資料中の当社および当社グループの現在の計画、見通し、戦略、確信などのうち、歴史的事実でないものは、将来の業績に関する見通しであり、これらは現時点において入手可能な情報から得られた当社経営陣の判断に基づくものですが、重大なリスクや不確実性を含んでいる情報から得られた多くの仮定および考えに基づきなされたものであります。実際の業績は、さまざまな要素によりこれら予測とは大きく異なる結果となり得ることをご承知おきください。

実際の業績に影響を与える要素には、経済情勢、特に消費動向、為替レートの変動、法律・行政制度の変化、競合会社の価格・製品戦略による圧力、当社の既存製品および新製品の販売力の低下、生産中断、当社の知的所有権に対する侵害、急速な技術革新、重大な訴訟における不利な判決等がありますが、業績に影響を与える要素はこれらに限定されるものではありません。

Forward-Looking Statements

Statements in this document, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors.

Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of the Company's intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

宝ホールディングス株式会社　財務・IR部
Takara Holdings Inc.　Financial＆Investor Relations Dept.

TEL 075(241)5124　FAX 075(241)5127
E-Mail ir@takara.co.jp

1. 宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

グループ別要約損益計算書 :Consolidated Statements of Income by Business Group (Summary)

(百万円 :Millions of Yen)

	2020年3月期 第1四半期	2021年3月期 第1四半期 Apr. 1, 2020 - Jun. 30, 2020		
	実績(a) FY2020 (1stQ) Actual (a)	実績(b) FY2021(1stQ) Actual (b)	増減(b-a) Change (b-a)	比(b/a) YOY% (b/a)
宝酒造 Takara Shuzo	36,009	37,601	1,592	104.4%
宝酒造インターナショナルグループ Takara Shuzo International Group	19,819	18,616	△ 1,203	93.9%
タカラバイオ グループ Takara Bio Group	8,650	6,938	△ 1,712	80.2%
その他 Other	7,682	6,858	△ 823	89.3%
調整額 Adjustment	△ 4,844	△ 4,635	208	―
売上高 Net sales	67,317	65,378	△ 1,938	97.1%
売上原価 Cost of sales	40,844	40,020	△ 824	98.0%
売上総利益 Gross profit	26,473	25,358	△ 1,114	95.8%
運送費、保管料 Transportation and storage	2,513	2,747	234	109.3%
広告宣伝費 Advertising	606	351	△ 254	58.0%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	8,676	8,718	41	100.5%
研究開発費 Research and development	1,037	1,262	225	121.7%
管理費、その他 Other, net	10,089	10,345	255	102.5%
販売費及び一般管理費 SG&A expenses	22,924	23,426	501	102.2%
宝酒造 Takara Shuzo	172	731	558	423.6%
宝酒造インターナショナルグループ Takara Shuzo International Group	678	133	△ 545	19.6%
タカラバイオ グループ Takara Bio Group	2,251	693	△ 1,557	30.8%
その他 Other	517	352	△ 164	68.1%
調整額 Adjustment	△ 71	21	92	―
営業利益(△:損失) Operating income(Δ:loss)	3,548	1,932	△ 1,616	54.5%
受取利息・配当金 Interest and Dividends income	375	323	△ 51	86.2%
その他営業外収益 Other, net	254	153	△ 101	60.2%
営業外収益 Non-operating income	630	476	△ 153	75.7%
支払利息 Interest and discounts expenses	101	99	△ 1	98.6%
その他営業外費用 Other, net	165	122	△ 42	74.2%
営業外費用 Non-operating expenses	266	222	△ 44	83.4%
経常利益(△:損失) Ordinary income(Δ:loss)	3,912	2,187	△ 1,725	55.9%
特別利益 Extraordinary gain	1	0	△ 0	83.9%
特別損失 Extraordinary loss	190	25	△ 164	47.2%
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	3,723	2,161	△ 1,561	58.1%
法人税、住民税及び事業税 Current income taxes 法人税等調整額 Deferred income taxes	1,105	927	△ 178	83.9%
四半期純利益(△:損失) Net income(Δ:loss)	2,617	1,234	△ 1,383	47.2%
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	647	78	△ 569	12.1%
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	1,969	1,156	△ 813	58.7%
設備投資額(有形・無形) Capital expenditures	1,613	1,550	△ 62	96.1%
減価償却費(有形・無形) Depreciation and Amortization	1,637	1,995	357	121.8%
のれん償却額 Amortization of goodwill	213	217	4	102.3%

営業外収益 Non-operating income	受取利息 55、受取配当金 267 、生命保険配当金 54 など Interest income 55 ,Dividend income 267 ,Dividend income of life insurance 54 etc.
営業外費用 Non-operating expenses	支払利息 65、社債利息 34、など Interest expenses 65, Interest on bonds 34 etc.
特別損失 Extraordinary loss	固定資産除売却損 19、投資有価証券評価損 5 など Loss on sales and retirement of noncurrent assets 19, Loss on valuation of investment securities 5 etc.

2. 宝酒造 :Takara Shuzo

要約損益計算書 :Statements of Income (Summary)

（百万円 :Millions of Yen）

	2020年3月期 第1四半期	2021年3月期 第1四半期 Apr. 1, 2020 - Jun. 30, 2020		
	実績(a) FY2020 (1stQ) Actual (a)	実績(b) FY2021(1stQ) Actual (b)	増減(b-a) Change (b-a)	比(b/a) YOY% (b/a)
焼酎 Shochu	12,297	12,445	147	101.2%
清酒 Sake	4,111	3,507	△ 603	85.3%
ソフトアルコール飲料 Light-alcohol refreshers	10,047	11,886	1,838	118.3%
その他酒類 Other liquors	1,592	1,352	△ 240	84.9%
本みりん Hon Mirin	3,191	3,127	△ 63	98.0%
その他調味料 Other seasonings	2,423	2,461	37	101.6%
原料用アルコール等 Raw alcohol	2,345	2,821	475	120.3%
売上高 Net sales	36,009	37,601	1,592	104.4%
売上原価 Cost of sales	21,868	23,015	1,147	105.2%
売上総利益 Gross profit	14,140	14,586	445	103.2%
運送費、保管料 Transportation and storage	1,911	2,026	115	106.0%
広告宣伝費 Advertising	564	308	△ 255	54.7%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	8,418	8,535	116	101.4%
研究開発費 Research and development	96	88	△ 7	91.9%
管理費、その他 Other, net	2,977	2,895	△ 82	97.2%
販売費及び一般管理費 SG&A expenses	13,967	13,854	△ 113	99.2%
営業利益（△：損失） Operating income(Δ:loss)	172	731	558	423.6%
営業外収益 Non-operating income	202	103	△ 98	51.3%
営業外費用 Non-operating expenses	80	61	△ 18	76.4%
経常利益（△：損失） Ordinary income(Δ:loss)	294	774	479	262.5%
特別利益 Extraordinary gain	—	—	—	—
特別損失 Extraordinary loss	102	11	△ 91	11.0%
税金等調整前四半期純利益（△：損失） Income(Δ:loss) before income taxes	192	762	570	396.6%
法人税、住民税及び事業税 Current income taxes	82	243	161	296.1%
法人税等調整額 Deferred income taxes				
四半期純利益（△：損失） Net income(Δ:loss)	110	519	409	471.5%

設備投資額（有形・無形） Capital expenditures	642	188	△ 453	29.4%
減価償却費（有形・無形） Depreciation and Amortization	540	693	152	128.3%

（注）2020年3月期第1四半期の実績において、「ソフトアルコール飲料」「その他酒類」の売上高の一部を組み替えております。

3. 宝酒造インターナショナルグループ :Takara Shuzo International Group

要約損益計算書 :Statements of Income (Summary)

（百万円 :Millions of Yen）

	2020年3月期 第1四半期	2021年3月期 第1四半期 Apr. 1, 2020 - Jun. 30, 2020		
	実績(a) FY2020 (1stQ) Actual (a)	実績(b) FY2021(1stQ) Actual (b)	増減(b−a) Change (b-a)	比(b/a) YOY% (b/a)
海外酒類事業 Overseas Alcoholic beverages business	2,493	2,506	13	100.5%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	17,774	16,460	△ 1,313	92.6%
その他 Other	24	28	3	113.0%
連結消去 Elimination	△ 473	△ 379	94	−
売上高 Net sales	19,819	18,616	△ 1,203	93.9%
売上原価 Cost of sales	14,259	13,237	△ 1,022	92.8%
売上総利益 Gross profit	5,559	5,379	△ 180	96.7%
運送費、保管料 Transportation and storage	580	606	26	104.6%
広告宣伝費 Advertising	21	21	△ 0	97.6%
販売促進費 Sales promotion	152	121	△ 31	79.6%
管理費、その他 Other, net	4,127	4,496	369	108.9%
販売費及び一般管理費 SG&A expenses	4,881	5,245	364	107.5%
海外酒類事業 Overseas Alcoholic beverages business	424	459	35	108.3%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	619	41	△ 578	6.7%
その他 Other	△ 241	△ 245	△ 4	−
連結消去 Elimination	△ 124	△ 121	2	−
営業利益（△：損失） Operating income(Δ:loss)	678	133	△ 545	19.6%
営業外収益 Non-operating income	66	46	△ 19	70.8%
営業外費用 Non-operating expenses	37	53	16	144.1%
経常利益（△：損失） Ordinary income(Δ:loss)	707	126	△ 580	17.9%
特別利益 Extraordinary gain	0	0	0	205.5%
特別損失 Extraordinary loss	4	1	△ 3	26.7%
税金等調整前四半期純利益（△：損失） Income(Δ:loss) before income taxes	702	125	△ 577	17.9%
法人税、住民税及び事業税 Current income taxes 法人税等調整額 Deferred income taxes	235	68	△ 166	29.2%
四半期純利益（△：損失） Net income(Δ:loss)	467	56	△ 410	12.2%
非支配株主に帰属する四半期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss)	21	△ 86	△ 107	−
親会社株主に帰属する四半期純利益（△：損失） Net income attributable to owners of the parent(Δ:loss)	446	143	△ 303	32.1%
設備投資額（有形・無形） Capital expenditures	607	934	327	153.9%
減価償却費（有形・無形） Depreciation and Amortization	292	352	60	120.6%
のれん償却額 Amortization of goodwill	87	93	6	107.3%

4. タカラバイオグループ :Takara Bio Group

要約損益計算書 :Statements of Income (Summary)

（百万円 :Millions of Yen）

	2020年3月期 第1四半期	2021年3月期 第1四半期 Apr. 1, 2020 - Jun. 30, 2020		
	実績(a) FY2020 (1stQ) Actual (a)	実績(b) FY2021(1stQ) Actual (b)	増減(b-a) Change (b-a)	比(b/a) YOY% (b/a)
研究用試薬 Research reagents	5,691	5,515	△ 175	96.9%
理化学機器 Scientific instruments	274	166	△ 107	60.6%
受託サービス Contracted service	781	1,137	355	145.5%
遺伝子医療 Gene therapy	1,903	119	△ 1,784	6.3%
売上高 Net sales	8,650	6,938	△ 1,712	80.2%
売上原価 Cost of sales	2,734	2,234	△ 500	81.7%
売上総利益 Gross profit	5,916	4,703	△ 1,212	79.5%
運送費、保管料 Transportation and storage	89	176	86	196.7%
広告宣伝費 Advertising	17	20	2	115.8%
販売促進費 Sales promotion	136	90	△ 45	66.5%
研究開発費 Research and development	939	1,172	233	124.8%
管理費、その他 Other, net	2,481	2,549	68	102.7%
販売費及び一般管理費 SG&A expenses	3,664	4,009	344	109.4%
営業利益（△：損失） Operating income(Δ:loss)	2,251	693	△ 1,557	30.8%
営業外収益 Non-operating income	62	81	19	131.0%
営業外費用 Non-operating expenses	113	29	△ 83	26.3%
経常利益（△：損失） Ordinary income(Δ:loss)	2,200	745	△ 1,455	33.9%
特別利益 Extraordinary gain	0	―	△ 0	―
特別損失 Extraordinary loss	9	8	△ 0	95.8%
税金等調整前四半期純利益（△：損失） Income(Δ:loss) before income taxes	2,191	736	△ 1,455	33.6%
法人税、住民税及び事業税 Current income taxes	595	326	△ 269	54.7%
法人税等調整額 Deferred income taxes				
四半期純利益（△：損失） Net income(Δ:loss)	1,596	410	△ 1,185	25.7%
非支配株主に帰属する四半期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss)	4	6	1	133.4%
親会社株主に帰属する四半期純利益（△：損失） Net income attributable to owners of the parent(Δ:loss)	1,591	404	△ 1,187	25.4%
設備投資額（有形・無形） Capital expenditures	361	281	△ 80	77.9%
減価償却費（有形・無形） Depreciation and Amortization	677	815	138	120.5%
のれん償却額 Amortization of goodwill	125	123	△ 1	98.8%

5. 6年間の財務サマリー(グループ別) :Six-Year Financial Summary by Business Group

宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

(百万円 :Millions of Yen)

		2016年3月期 第1四半期 FY2016 (1stQ)	2017年3月期 第1四半期 FY2017 (1stQ)	2018年3月期 第1四半期 FY2018 (1stQ)	2019年3月期 第1四半期 FY2019 (1stQ)	2020年3月期 第1四半期 FY2020 (1stQ)	2021年3月期 第1四半期 FY2021 (1stQ)	前期対比 Change from FY2020(1stQ) 増減 Change	比 YOY%
売上高	Net sales	50,938	52,311	63,368	66,969	67,317	65,378	△ 1,938	97.1%
売上原価	Cost of sales	31,323	31,391	38,705	40,387	40,844	40,020	△ 824	98.0%
(売上高原価率)	(Ratio to Net sales)	61.5%	60.0%	61.1%	60.3%	60.7%	61.2%	+0.5pt	–
売上総利益	Gross profit	19,615	20,919	24,662	26,582	26,473	25,358	△ 1,114	95.8%
販売費及び一般管理費	SG&A expenses	18,966	19,289	22,588	22,582	22,924	23,426	501	102.2%
(売上高販管費率)	(Ratio to Net sales)	37.2%	36.9%	35.6%	33.7%	34.1%	35.8%	+1.8pt	–
営業利益(△:損失)	Operating income(Δ:loss)	649	1,630	2,074	4,000	3,548	1,932	△ 1,616	54.5%
(売上高営業利益率)	(Ratio to Net Sales)	1.3%	3.1%	3.3%	6.0%	5.3%	3.0%	-2.3pt	–
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.	8,169	8,370	8,886	8,426	8,676	8,718	41	100.5%
(売上高販促費率)	(Ratio to Net sales)	16.0%	16.0%	14.0%	12.6%	12.9%	13.3%	+0.4pt	–
研究開発費	R&D expenses	1,103	1,045	1,201	1,111	1,037	1,262	225	121.7%
(売上高研究開発費率)	(Ratio to Net sales)	2.2%	2.0%	1.9%	1.7%	1.5%	1.9%	+0.4pt	–
設備投資額(有形・無形)	Capital expenditures	365	681	946	1,085	1,613	1,550	△ 62	96.1%
減価償却費(有形・無形)	Depreciation and Amortization	1,216	1,245	1,522	1,578	1,637	1,995	357	121.8%
のれん償却額	Amortization of goodwill	133	122	194	215	213	217	4	102.3%

宝酒造 :Takara Shuzo Co., Ltd.

(百万円 :Millions of Yen)

		2016年3月期 第1四半期 FY2016 (1stQ)	2017年3月期 第1四半期 FY2017 (1stQ)	2018年3月期 第1四半期 FY2018 (1stQ)	2019年3月期 第1四半期 FY2019 (1stQ)	2020年3月期 第1四半期 FY2020 (1stQ)	2021年3月期 第1四半期 FY2021 (1stQ)	前期対比 Change from FY2020(1stQ) 増減 Change	比 YOY%
売上高	Net sales	–	34,235	36,029	36,772	36,009	37,601	1,592	104.4%
売上原価	Cost of sales	–	20,797	21,665	22,161	21,868	23,015	1,147	105.2%
(売上高原価率)	(Ratio to Net sales)		60.7%	60.1%	60.3%	60.7%	61.2%	+0.5pt	–
売上総利益	Gross profit		13,438	14,363	14,610	14,140	14,586	445	103.2%
販売費及び一般管理費	SG&A expenses		13,523	14,212	13,759	13,967	13,854	△ 113	99.2%
(売上高販管費率)	(Ratio to Net sales)		39.5%	39.4%	37.4%	38.8%	36.8%	-1.9pt	–
営業利益(△:損失)	Operating income(Δ:loss)		△ 85	151	851	172	731	558	423.6%
(売上高営業利益率)	(Ratio to Net sales)		–	0.4%	2.3%	0.5%	1.9%	+1.5pt	–
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.		8,066	8,561	8,152	8,418	8,535	116	101.4%
(売上高販促費率)	(Ratio to Net sales)		23.6%	23.8%	22.2%	23.4%	22.7%	-0.7pt	–
設備投資額(有形・無形)	Capital expenditures	–	211	315	79	642	188	△ 453	29.4%
減価償却費(有形・無形)	Depreciation and Amortization	–	516	516	527	540	693	152	128.3%

2018年3月期からの新セグメントです。
This is a new segment from the fiscal year ended March 2018.

宝酒造インターナショナルグループ :Takara Shuzo International Group

(百万円 :Millions of Yen)

		2016年3月期 第1四半期 FY2016 (1stQ)	2017年3月期 第1四半期 FY2017 (1stQ)	2018年3月期 第1四半期 FY2018 (1stQ)	2019年3月期 第1四半期 FY2019 (1stQ)	2020年3月期 第1四半期 FY2020 (1stQ)	2021年3月期 第1四半期 FY2021 (1stQ)	前期対比 Change from FY2020(1stQ) 増減 Change	比 YOY%
売上高	Net sales	–	7,432	16,450	18,270	19,819	18,616	△ 1,203	93.9%
売上原価	Cost of sales	–	4,989	11,683	12,721	14,259	13,237	△ 1,022	92.8%
(売上高原価率)	(Ratio to Net sales)		67.1%	71.0%	69.6%	71.9%	71.1%	-0.8pt	–
売上総利益	Gross profit		2,443	4,767	5,549	5,559	5,379	△ 180	96.7%
販売費及び一般管理費	SG&A expenses		1,837	3,807	4,399	4,881	5,245	364	107.5%
(売上高販管費率)	(Ratio to Net sales)		24.7%	23.1%	24.1%	24.6%	28.2%	+3.5pt	–
営業利益(△:損失)	Operating income(Δ:loss)		606	960	1,150	678	133	△ 545	19.6%
(売上高営業利益率)	(Ratio to Net sales)		8.2%	5.8%	6.3%	3.4%	0.7%	-2.7pt	–
設備投資額(有形・無形)	Capital expenditures		154	322	261	607	934	327	153.9%
減価償却費(有形・無形)	Depreciation and Amortization	–	146	230	247	292	352	60	120.6%
のれん償却額	Amortization of goodwill	–	78	85	92	87	93	6	107.3%

2018年3月期からの新セグメントです。
This is a new segment from the fiscal year ended March 2018.

タカラバイオグループ :Takara Bio Group

(百万円 :Millions of Yen)

		2016年3月期 第1四半期 FY2016 (1stQ)	2017年3月期 第1四半期 FY2017 (1stQ)	2018年3月期 第1四半期 FY2018 (1stQ)	2019年3月期 第1四半期 FY2019 (1stQ)	2020年3月期 第1四半期 FY2020 (1stQ)	2021年3月期 第1四半期 FY2021 (1stQ)	前期対比 Change from FY2020(1stQ) 増減 Change	比 YOY%
売上高	Net sales	5,761	6,306	6,355	8,847	8,650	6,938	△ 1,712	80.2%
売上原価	Cost of sales	2,439	2,439	2,245	3,491	2,734	2,234	△ 500	81.7%
(売上高原価率)	(Ratio to Net sales)	42.3%	38.7%	35.3%	39.5%	31.6%	32.2%	+0.6pt	–
売上総利益	Gross profit	3,322	3,866	4,109	5,355	5,916	4,703	△ 1,212	79.5%
販売費及び一般管理費	SG&A expenses	3,210	3,223	3,846	3,811	3,664	4,009	344	109.4%
(売上高販管費率)	(Ratio to Net sales)	55.7%	51.1%	60.5%	43.1%	42.4%	57.8%	+15.4pt	–
営業利益(△:損失)	Operating income(Δ:loss)	111	643	262	1,544	2,251	693	△ 1,557	30.8%
(売上高営業利益率)	(Ratio to Net sales)	1.9%	10.2%	4.1%	17.5%	26.0%	10.0%	-16.0pt	–
研究開発費	R&D expenses	1,020	950	1,103	1,014	939	1,172	233	124.8%
(売上高研究開発費率)	(Ratio to Net sales)	17.7%	15.1%	17.4%	11.5%	10.9%	16.9%	+6.0pt	–
設備投資額(有形・無形)	Capital expenditures	90	211	174	678	361	281	△ 80	77.9%
減価償却費(有形・無形)	Depreciation and Amortization	392	436	580	669	677	815	138	120.5%
のれん償却額	Amortization of goodwill	44	43	109	123	125	123	△ 1	98.8%

6. 2021年3月期第1四半期 参考資料 :Reference Data for the First Quarter Ended June 30, 2020

① 為替前提及び売上高に対する為替レート変動の影響 :Exchange rates and effect of change in exchange rates on net sales

◆為替前提(海外子会社P/L換算用):Exchange rates for the income statement of oversea subsidiaries

(円 : Yen)

	2020年3月期 第1四半期	2021年3月期 第1四半期 Apr. 1, 2020 - Jun. 30, 2020	
	実績(a) FY2020 (1stQ) Actual (a)	実績(b) FY2021(1stQ) Actual (b)	前期差 Change(b-a)
米ドル : US dollar	110.23	108.91	△ 1.32
ポンド: Pound	143.74	139.39	△ 4.35
ユーロ: Euro	125.16	120.13	△ 5.03
人民元: Yuan	16.33	15.59	△ 0.74
100ウォン: 100 Won	9.80	9.13	△ 0.67
インドルピー: Rupee	1.57	1.51	△ 0.06
ｽｳｪｰﾃﾞﾝｸﾛｰﾅ :Sweden krona	12.01	11.27	△ 0.74
ｼﾝｶﾞﾎﾟｰﾙﾄﾞﾙ :Singapore dollar	81.37	78.63	△ 2.74
ｵｰｽﾄﾗﾘｱﾄﾞﾙ :Australian dollar	78.55	71.62	△ 6.93

◆売上高に対する為替レート変動の影響額 :Effect of change in exchange rates on net sales

(百万円 :Millions of Yen)

	対前期 Change from FY2020(1stQ)
宝ホールディングス 計 Net sales of Takara Holdings Inc. -Consolidated-	△ 623
うち宝酒造ｲﾝﾀｰﾅｼｮﾅﾙｸﾞﾙｰﾌﾟ Net sales of Takara Shuzo International Group	△ 495
海外酒類事業 Overseas Alcoholic beverages business	△ 45
海外日本食材卸事業 Japanese food wholesale business in overseas markets	△ 454
その他 Other	―
連結消去 Elimination	4
うちタカラバイオグループ Net sales of Takara Bio Group	△ 129
研究用試薬 Research reagents	△ 121
理化学機器 Scientific instruments	△ 1
受託サービス Contracted service	△ 5
遺伝子医療 Gene therapy	―

② 海外売上高比率の推移 :Change in overseas sales ratio

(百万円 :Millions of Yen)

	2020年3月期第1四半期 実績 FY2020(1stQ) Actual			2021年3月期第1四半期 実績 FY2021(1stQ) Actual		
	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio
宝酒造 Takara Shuzo	36,009	―	―	37,601	―	―
宝酒造ｲﾝﾀｰﾅｼｮﾅﾙｸﾞﾙｰﾌﾟ Takara Shuzo International Group	19,819	19,718	99.5%	18,616	18,529	99.5%
タカラバイオグループ Takara Bio Group	8,650	4,713	54.5%	6,938	4,448	64.1%
その他および調整額 Other / Adjustment	2,837	―	―	2,222	―	―
宝ホールディングス(連結) Takara Holdings Inc. -Consolidated-	67,317	24,432	36.3%	65,378	22,977	35.1%

③ 海外主要子会社の業績 :Financial Forecast of major overseas subsidiaries

		2020年3月期第1四半期 実績 FY2020(1stQ) Actual		2021年3月期第1四半期 実績 FY2021(1stQ) Actual	
		売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
米国宝酒造	千 US ドル :Thousands of US dollar	8,576	810	7,558	Δ 29
Takara Sake USA Inc.	百 万 円 :Millions of Yen	945	89	823	Δ 3
宝酒造食品	千 元 :Thousands of Yuan	12,038	132	6,860	Δ 473
Takara Shuzo Foods Co.,Ltd.	百 万 円 :Millions of Yen	196	2	106	Δ 7
トマーチン	千 ポ ン ド :Thousands of Pound	3,723	699	4,646	1,062
The Tomatin Distillery Co.,Ltd.	百 万 円 :Millions of Yen	535	100	647	148
ｴｲｼﾞ・ｲﾝﾀｰﾅｼｮﾅﾙ	千 US ドル :Thousands of US dollar	5,591	2,486	7,288	3,257
AGE INTERNATIONAL,INC.	百 万 円 :Millions of Yen	616	274	793	354
フーデックスグループ	千 ユ ー ロ :Thousands of Euro	41,646	3,668	38,946	2,299
FOODEX Group	百 万 円 :Millions of Yen	5,212	459	4,678	276
タザキフーズ	千 ポ ン ド :Thousands of Pound	10,861	446	11,923	607
TAZAKI FOODS LTD.	百 万 円 :Millions of Yen	1,561	64	1,662	84
ミューチャルトレーディング	千 US ドル :Thousands of US dollar	89,849	1,511	82,329	Δ 2,414
Mutual Trading Co., Inc.	百 万 円 :Millions of Yen	9,904	166	8,966	Δ 262
ニッポンフード	千 AUS ドル :Thousands of Australian dollar	13,964	Δ 893	14,110	Δ 186
Nippon Food Supplies Company Pty Ltd	百 万 円 :Millions of Yen	1,096	Δ 70	1,010	Δ 13
ﾀｶﾗﾊﾞｲｵﾖｰﾛｯﾊﾟS.A.S.(連結)	千 ユ ー ロ :Thousands of Euro	5,916	162	6,057	51
Takara Bio Europe S.A.S. Consolidated	百 万 円 :Millions of Yen	740	20	727	6
宝生物工程(大連)	千 元 :Thousands of Yuan	49,905	11,755	67,391	26,673
Takara Biotechnology (Dalian) Co.,Ltd.	百 万 円 :Millions of Yen	814	191	1,050	415
宝日医生物技術(北京)	千 元 :Thousands of Yuan	87,067	15,412	71,657	15,394
Takara Biomedical Technology(Beijing) Co., Ltd.	百 万 円 :Millions of Yen	1,421	251	1,117	239
ﾀｶﾗｺﾘｱﾊﾞｲｵﾒﾃﾞｨｶﾙ	百 万 ウ ォ ン :Millions of Won	2,567	441	2,211	283
Takara Korea Biomedical Inc.	百 万 円 :Millions of Yen	251	43	201	25
タカラバイオDSSインド	千 ｲﾝﾄﾞﾙﾋﾟｰ :Thousands of Rupee	66,608	7,652	68,585	11,457
DSS Takara Bio India Private Limited	百 万 円 :Millions of Yen	104	12	103	17
タカラバイオUSA	千 US ドル :Thousands of US dollar	23,295	1,519	24,387	1,693
Takara Bio USA, Inc.	百 万 円 :Millions of Yen	2,567	167	2,655	184

④ 宝酒造 売上総利益増減要因 :Factors of change in Gross profit of Takara Shuzo

(百万円 :Millions of Yen)

	対前期増減 Change from FY2020(1stQ)		
	増減計 Total Change	数量差 Change in quantities	単価差 Change in unit price
売上総利益 計 Gross profit	+445	+701	Δ 255
(主な内訳)			
焼酎 Shochu	+89	+6	+82
清酒 Sake	Δ 284	Δ 223	Δ 61
ｿﾌﾄｱﾙｺｰﾙ飲料 Light-alcohol refreshers	+753	+1,068	Δ 315
本みりん Hon Mirin	Δ 54	Δ 27	Δ 27
(参考)原価コストダウン Reference :Cost reduction	Δ 152	※上記数量差および単価差に含む *Included in changes above	

※利益の増加要因を「+」、減少要因を「△」で表示

*An increasing factor and a decreasing factor on profit are shown 「+」 and 「△」, respectively

⑤ 宝ホールディングス(連結)要約損益計算書(p.1)における「その他」の内訳

Breakdown of "Other" segment in the Consolidated Statemnets of Income of Takara Holdings Inc. (Summary) (p.1)

	2020年3月期第1四半期 実績 FY2020(1stQ) Actual		2021年3月期第1四半期 実績 FY2021(1stQ) Actual	
	売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
物流事業 Transportation	3,507	135	3,369	123
宝ホールディングス(不動産事業) Takara Holdings (Real estate business)	133	111	127	106
その他 Other	4,041	269	3,361	122
「その他」計 Total "Other"	7,682	517	6,858	352

7. 連結業績予想数値の修正 :Revision of Consolidated Business Results Forecast

① 2021年3月期第2四半期 : The Second Quarter Ending September 30, 2020

宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

(百万円、% :Millions of Yen / %)

	売上高 Net sales	営業利益 Operating income	経常利益 Ordinary income	親会社株主に帰属する当期純利益 Net income attributable to owners of the parent	1株当り当期純利益 Net income per share
					円 銭 Yen
前回発表予想(2020年5月14日発表)(A) Previous forecast (A) (May 14, 2020, announcement)	120,000	300	400	0	0.00
今回修正予想(B) Revised forecast (B)	122,504	2,180	2,265	760	3.84
増減額(B−A) Difference (B−A)	2,504	1,880	1,865	760	−
増減率(%) Difference (%)	2.1	626.7	466.3	−	−
ご参考:前期実績(2020年3月期第2四半期) Reference: Previous business results(the Second Quarter Ended September 30, 2019)	137,502	7,623	7,871	4,374	21.91

タカラバイオグループ :Takara Bio Group

(百万円、% :Millions of Yen / %)

	売上高 Net sales	営業利益 Operating income	経常利益 Ordinary income	親会社株主に帰属する当期純利益 Net income attributable to owners of the parent
前回発表予想(2020年5月14日発表)(A) Previous forecast (A) (May 14, 2020, announcement)	14,365	619	693	0
今回修正予想(B) Revised forecast (B)	16,870	2,500	2,559	1,248
増減額(B−A) Difference (B−A)	2,504	1,880	1,865	1,248
増減率(%) Difference (%)	17.4	303.9	269.0	−
ご参考:前期実績(2020年3月期第2四半期) Reference: Previous business results(the Second Quarter Ended September 30, 2019)	16,450	3,035	2,961	2,075

(参考)宝酒造および宝酒造インターナショナルグループは2020年5月14日発表予想を据え置いております。

宝酒造 :Takara Shuzo

(百万円、% :Millions of Yen / %)

	売上高 Net sales	営業利益 Operating income	経常利益 Ordinary income	当期純利益 Net income
2020年5月14日発表予想(A) Previous forecast (A) (May 14, 2020, announcement)	74,428	954	948	578
前期実績(2020年3月期第2四半期)(B) Previous business results(the Second Quarter Ended September 30, 2019)	75,135	2,082	2,139	1,329
増減額(A−B) Difference (A−B)	△ 707	△ 1,128	△ 1,191	△ 751
増減率(%) Difference (%)	△ 0.9	△ 54.2	△ 55.7	△ 56.5

宝酒造インターナショナルグループ :Takara Shuzo International Group

(百万円、% :Millions of Yen / %)

	売上高 Net sales	営業利益 Operating income	経常利益 Ordinary income	親会社株主に帰属する当期純利益 Net income attributable to owners
2020年5月14日発表予想(A) Previous forecast (A) (May 14, 2020, announcement)	26,355	△ 1,952	△ 1,984	△ 1,216
前期実績(2020年3月期第2四半期)(B) Previous business results(the Second Quarter Ended September 30, 2019)	40,477	1,565	1,607	1,048
増減額(A−B) Difference (A−B)	△ 14,122	△ 3,517	△ 3,591	△ 2,264
増減率(%) Difference (%)	△ 34.9	△ 224.7	△ 223.5	△ 216.0

② 2021年3月期 : The Year Ending March 31, 2021

宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

(百万円、% :Millions of Yen / %)

	売上高 Net sales	営業利益 Operating income	経常利益 Ordinary income	親会社株主に帰属する当期純利益 Net income attributable to owners of the parent	1株当り当期純利益 Net income per share
					円 銭 Yen
前回発表予想(2020年5月14日発表)(A) Previous forecast (A) (May 14, 2020, announcement)	270,000	10,000	10,200	5,100	25.80
今回修正予想(B) Revised forecast (B)	275,800	12,000	12,200	5,952	30.11
増減額(B−A) Difference (B−A)	5,800	2,000	2,000	852	−
増減率(%) Difference (%)	2.1	20.0	19.6	16.7	−
ご参考:前期実績(2020年3月期) Reference: Previous business results (Year ended March 31, 2020)	281,191	15,836	16,269	8,980	45.11

タカラバイオグループ :Takara Bio Group

(百万円、% :Millions of Yen / %)

	売上高 Net sales	営業利益 Operating income	経常利益 Ordinary income	親会社株主に帰属する当期純利益 Net income attributable to owners of the parent
前回発表予想(2020年5月14日発表)(A) Previous forecast (A) (May 14, 2020, announcement)	33,800	4,500	4,600	2,600
今回修正予想(B) Revised forecast (B)	39,600	6,500	6,600	4,000
増減額(B−A) Difference (B−A)	5,800	2,000	2,000	1,400
増減率(%) Difference (%)	17.2	44.4	43.5	53.8
ご参考:前期実績(2020年3月期) Reference: Previous business results (Year ended March 31, 2020)	34,565	6,274	6,347	3,819

(参考)宝酒造および宝酒造インターナショナルグループは2020年5月14日発表予想を据え置いております。

宝酒造 :Takara Shuzo

(百万円、% :Millions of Yen / %)

	売上高 Net sales	営業利益 Operating income	経常利益 Ordinary income	当期純利益 Net income
2020年5月14日発表予想(A) Previous forecast (A) (May 14, 2020, announcement)	155,157	4,285	4,209	2,640
前期実績(2020年3月期)(B) Previous business results(B)(Year ended March 31, 2020)	153,141	4,175	4,113	2,532
増減額(A−B) Difference (A−B)	2,016	110	96	108
増減率(%) Difference (%)	1.3	2.6	2.3	4.3

宝酒造インターナショナルグループ :Takara Shuzo International Group

(百万円、% :Millions of Yen / %)

	売上高 Net sales	営業利益 Operating income	経常利益 Ordinary income	親会社株主に帰属する当期純利益 Net income attributable to owners
2020年5月14日発表予想(A) Previous forecast (A) (May 14, 2020, announcement)	70,530	145	92	0
前期実績(2020年3月期)(B) Previous business results(B)(Year ended March 31, 2020)	82,765	3,532	3,507	2,170
増減額(A−B) Difference (A−B)	△ 12,235	△ 3,387	△ 3,415	△ 2,170
増減率(%) Difference (%)	△ 14.8	△ 95.9	△ 97.4	△ 100.0